cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2013-5-75-80cardiovascular-239Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMКОМБИНИРОВАННАЯ ТЕРАПИЯ В ЛЕЧЕНИИ АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ: ЭФФЕКТИВНОСТЬ СОЧЕТАНИЯ ЛЕРКАНИДИПИНА И ЭНАЛАПРИЛАCOMBINATION THERAPY IN THE MANAGEMENT OF ARTERIAL HYPERTENSION: EFFECTIVENESS OF THE LERCANIDIPINE AND ENALAPRIL COMBINATIONМинушкинаЛ. О.MinushkinaL. O.

профессор кафедры терапии, кардиологии и функциональной диагностики

Тел.: 7 (499) 146–41–51; факс +7 (499) 144–16–34 

tel.: 7 (499) 146–41–51; fax +7 (499) 144–16–34 

minushkina@mail.ruФГБУ “Учебно-научный медицинский центр” УД Президента РФ, МоскваРоссияMedical Education and Research Centre, RF President Administration, MoscowRussian Federation2013201020131257580Copyright © Минушкина Л.О., 20132013Минушкина Л.О.Minushkina L.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/239

Представлены доказательства преимуществ использования фиксированных комбинаций в лечении артериальной гипертонии. Рассмотрены возможности комбинированной терапии с использованием дигидропиридинового антагониста кальция 3 поколения лерканидипина и ингибитора ангиотензинпревращающего фермента эналаприла. Лерканидипин отличается высокой вазоселективностью и липофильностью, хорошей антигипертензивной эффективностью, большой длительностью и постепенным наступлением эффекта. Приведены имеющиеся в литературе доказательства эффективности комбинации лерканидипин/эналаприл. Эта комбинация дает возможность для достижения более выраженного снижения артериального давления, в т. ч. и у больных пожилого возраста, пациентов с сахарным диабетом и ожирением. Сочетание фармакологических эффектов лерканидипина и эналаприла создает дополнительные возможности для органопротекции и снижения риска побочных эффектов лечения. 

This review presents the evidence on the benefits of fixed-dose combination therapy for arterial hypertension management. The focus is on the combination of a third-generation dihydropyridine calcium antagonist lercanidipine and an ACE inhibitor enalapril. Lercanidipine is characterised by high vascular selectivity and lipophilicity, good antihypertensive effectiveness, and prolonged, gradually developing therapeutic effects. Literature data on the effectiveness of the lercanidipine-enalapril combination are presented. This combination facilitates a marked reduction in blood pressure levels, which is particularly relevant for elderly patients and patients with diabetes mellitus or obesity. The combination of pharmacologic effects of lercanidipine and enalapril provides additional benefits in terms of organ protection and reduction of adverse effects of the antihypertensive treatment. 

лерканидипинэналаприлфиксированная комбинацияартериальная гипертонияlercanidipineenalaprilfixed-dose combinationarterial hypertensionReferencesWald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290–300.Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399–407.Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646–53.Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009; 53: 646–53.Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906.Jamerson K, Weber MA, Bakris GL, et al. for the ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.Jamerson K, Weber MA, Bakris GL, et al. for the ACCOMPLISH Trial Investigators Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–28.Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–51.Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–51.Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs 1999; 8 (7): 1043–62.Meredith PA. Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs 1999; 8 (7): 1043–62.Ciro A. Active dose findings for lercanidipine in a doubleblind, placebo￾controlled design in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S21–5.Ciro A. Active dose findings for lercanidipine in a doubleblind, placebo￾controlled design in patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1997; 29 (Suppl 2): S21–5.Paterna S, Licata A, Arnone S, et al. Lercanidipine in two different dosage regimens as a sole treatment of severe essential hypertension. J Cardiovasc Pharmac 1997; 29: 50–5.Paterna S, Licata A, Arnone S, et al. Lercanidipine in two different dosage regimens as a sole treatment of severe essential hypertension. J Cardiovasc Pharmac 1997; 29: 50–5.McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.McClellan KJ, Jarvis B. Lercanidipine: a review of its use in hypertension. Drugs 2000; 60 (5): 1123–40.Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259–66.Dalla Vestra M, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab 2004; 17 (5): 259–66.Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.Robles NR, Ocon J, Gomez CF, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail 2005; 27 (1): 73–80.Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41 (4): 950–5.Taddei S, Virdis A, Ghiadoni L, et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension 2003; 41 (4): 950–5.Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension￾related vascular structural changes. Blood Press 2006; 15 (5): 268–74.Grassi G, Quarti-Trevano F, Scopelliti F, et al. Effects of long-term lercanidipine or hydrochlorothiazide administration on hypertension￾related vascular structural changes. Blood Press 2006; 15 (5): 268–74.Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54 (2): 409–13.Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009; 54 (2): 409–13.Tisaire-Sánchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag 2006; 2 (4): 491–8.Tisaire-Sánchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vasc Health Risk Manag 2006; 2 (4): 491–8.Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3: 999–1005.Veronesi M, Cicero AF, Prandin MG, et al. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. Vasc Health Risk Manag 2007; 3: 999–1005.Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.Cicero AF, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32 (2): 192–7.Robles NR, Romero B, de Vinuesa EG, et al. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32 (2): 192–7.Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4 (6): 479–82.Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Rep 2002; 4 (6): 479–82.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence. 2012; 6: 449–55.Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Patient Prefer Adherence. 2012; 6: 449–55.Hair PI, Scoot LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67 (1): 95–106.Hair PI, Scoot LJ, Perry CM. Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67 (1): 95–106.Mancia G. Effects on Office and Home Blood Pressure (BP) of Lercanidipine￾Enalapril Combination. The FELT Study. ESH congress materials 2012; 10.Mancia G. Effects on Office and Home Blood Pressure (BP) of Lercanidipine￾Enalapril Combination. The FELT Study. ESH congress materials 2012; 10.Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007; 21 (12): 917–24.Puig JG, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hum Hypertens 2007; 21 (12): 917–24.Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006; 24 (1): 185–92.Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006; 24 (1): 185–92.Cleophas TJ, van Ouwerkerk BM, van der Meulen J, at al. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 2001; 52 (7): 469–75.Cleophas TJ, van Ouwerkerk BM, van der Meulen J, at al. Diabetics with hypertension not controlled with ACE inhibitors: alternate therapies. Angiology 2001; 52 (7): 469–75.Grassi G. Sympathometabolic profile of lercanidipine/enalapril combination treatment in obese hypertensive patients. J Hypertension 2010; 28, Suppl A: e605–6.Grassi G. Sympathometabolic profile of lercanidipine/enalapril combination treatment in obese hypertensive patients. J Hypertension 2010; 28, Suppl A: e605–6.Scholze J, Bramlage P, Trenkwalder P, et al. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011; 12 (18): 2771–9.Scholze J, Bramlage P, Trenkwalder P, et al. Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. Expert Opin Pharmacother 2011; 12 (18): 2771–9.Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60 (3): 124–30.Rump LC. Efficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertension. Arzneimittelforschung 2010; 60 (3): 124–30.Abellán Alemán J, Gil Guillén V, Merino Sánchez J, et al. Study of drug surveillance with lercanidipine. Data on ZANyCONTROL studyNext Document. Hipertensión 2009; 26 (03): 105–11.Abellán Alemán J, Gil Guillén V, Merino Sánchez J, et al. Study of drug surveillance with lercanidipine. Data on ZANyCONTROL studyNext Document. Hipertensión 2009; 26 (03): 105–11.

The authors declare that there are no conflicts of interest present.